Rochelle Bagatell MD

Rochelle Bagatell, MD, is Professor of Pediatrics at Perelman School of Medicine at the University of Pennsylvania. She is a pediatric oncologist with expertise in the care of children with extra-cranial solid tumors. She is the Solid Tumor Section Chief at Children's Hospital of Philadelphia and has a particular interest in the treatment of patients with neuroblastoma.

Dr. Bagatell completed her education, pediatric residency, and pediatric internship at the University of Arizona. She went on to complete additional fellowships in pediatric hematology and oncology at Children's Memorial Hospital, Northwestern University, and University of Arizona. She is board-certified in pediatric hematology-oncology.

Dr. Bagatell's research focuses on the development and evaluation of new treatments for children diagnosed with neuroblastoma. She has played an integral part in several prospective clinical trials through the Children's Oncology Group (COG), a cooperative group comprised of over 240 pediatric oncology centers. She previously led two Phase 2 trials for patients with relapsed and refractory neuroblastoma in the COG, and has chaired a Phase 1 trial of combination therapy for children with neuroblastoma and other solid tumors. She has served as chair of the High-Risk Task Force within the COG Neuroblastoma Committee and was a key contributor to two pilot studies for newly diagnosed patients.

Dr. Bagatell currently serves as Chair of the COG Neuroblastoma Committee and is the vice-chair of a recently completed Phase 3 trial for newly diagnosed high-risk patients that incorporated targeted agents into multi-modality therapy. She is also involved in recently completed studies for patients with minimal residual disease following stem cell transplantation, as well as studies focused on relapsed/refractory disease. She is actively involved in translational studies accompanying these trials, with a goal of identifying biomarkers to guide future therapeutic decision-making.

Dr. Bagatell is the Chair of the NCCN Neuroblastoma Panel.